PORTLAND, Ore.--(BUSINESS WIRE)--Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI’s partner Cook Group Inc. presented promising preliminary observations at the 18th Annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. last week. The multi-center APPRAISAL study is designed to evaluate Resten-MPTM delivered intravenously via microparticle technology, in conjunction with placement of one or more bare-metal stents.
